📢 #ESMO26 同期论文 - CheckMate 8HW 中 nivolumab 联合 ipilimumab 对比 nivolumab 或化疗治疗微卫星不稳定性高/错配修复缺陷型转移性结直肠癌的最终结果。
🔗https://shorturl.at/LFyqF
@sara_lonardi1 @MyriamChalabi
94 浏览 · 1 赞 · 1 转发 · 1 回复
Emotional distress (ED) upfront neoadjuvant ipilimumab + nivolumab (IPI+NIVO) is associated with lower pathological response and toxicity
https://esmocongress.esmo.orgResults from a phase 3 trial of neoadjuvant (neoadj) chemotherapy alone vs in combination with nivolumab followed by postsurgical adjuvant nivolumab in patients (pts) with muscle-invasive bladder cancer (MIBC)
https://esmocongress.esmo.orgFinal pathological and radiological outcomes and initial EFS from a blinded, exploratory phase 2 trial of nivolumab ± visugromab in MIBC (GDFather-NEO)
https://esmocongress.esmo.orgPrimary analysis of HBI-8000-303: A randomized phase 3 trial of nivolumab plus HBI-8000 or placebo in advanced melanoma
https://esmocongress.esmo.org- **标题 / Title：** Efficacy of Tedopi Plus Docetaxel or Tedopi Plus Nivolumab as Second-line Therapy in Metastatic Non-small-cell Lung Cancer Progressing After First-line Chemo-immunotherapy (Combi-TED)
https://esmocongress.esmo.org- Erik J.@PrblmXpert
@Annals_Oncology @sara_lonardi1 @MyriamChalabi 5-year OS of 74% vs 62% is a substantial gain for patients. I think CheckMate 8HW firmly settles the long-term value of dual ICI in MSI-high/dMMR mCRC. #ESMO26
来源：Annals of Oncology · x.com